Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.04 USD
Change Today -0.05 / -2.39%
Volume 9.9K
GNVC On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

genvec inc (GNVC) Snapshot

Open
$2.10
Previous Close
$2.09
Day High
$2.13
Day Low
$2.04
52 Week High
02/9/15 - $4.67
52 Week Low
10/15/14 - $1.61
Market Cap
35.2M
Average Volume 10 Days
41.2K
EPS TTM
$-0.18
Shares Outstanding
17.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENVEC INC (GNVC)

genvec inc (GNVC) Related Bloomberg News

View More Bloomberg News

genvec inc (GNVC) Related Businessweek News

No Related Businessweek News Found

genvec inc (GNVC) Details

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines in the United States. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its lead product candidate includes CGF166, which is in Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. The company also develops vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, Enterovirus D68, and malaria, as well as vaccines against foot-and-mouth disease in the area of animal health. It has a collaboration agreement with TheraBiologics to develop cancer therapeutics. The company was founded in 1992 and is based in Gaithersburg, Maryland.

11 Employees
Last Reported Date: 03/24/15
Founded in 1992

genvec inc (GNVC) Top Compensated Officers

Chief Executive Officer, President, Corporate...
Total Annual Compensation: $375.0K
Senior Vice President of Development
Total Annual Compensation: $278.1K
Chief Scientific Officer
Total Annual Compensation: $310.7K
Compensation as of Fiscal Year 2014.

genvec inc (GNVC) Key Developments

GenVec and Washington University at St. Louis Form Collaboration to Discover Targeted Adenovector-Based Therapeutics And Vaccines

GenVec, Inc. announced a multi-faceted collaboration with Dr. David T. Curiel and his team from the School of Medicine at Washington University St. Louis (WUSTL).  Dr. Curiel is the director of the Biologic Therapeutic Center and the Cancer Biology Division within the Department of Radiation Oncology. Under the collaboration, GenVec and the WUSTL team will create modified versions of GenVec's gorilla adenovectors that incorporate specialized targeting antibodies on the surface of the vectors. These antibodies are produced only by camels, alpacas and other camelids and are smaller and more stable in intracellular environments than their mouse or human counterparts. The ultimate goal of this collaboration will be to create highly targeted therapeutics and vaccines. The WUSTL team has conducted in vitro research using human cells grown in the lab to demonstrate that camelid antibodies can be used to target genetically engineered viruses specifically to cancer cells.  Camelid antibodies are smaller than typical antibody proteins and do not unfold in the harsh environment inside cells, allowing them to retain their binding specificity, and thus, their targeting capability.  Paired with the right viral vector, and combined with other targeting moieties, these antibodies can potentially be used for pinpoint delivery of viruses to various target cell types. In preclinical testing, GenVec's gorilla adenovectors have shown superior performance, particularly for molecular vaccine applications. The purpose of the early stage of GenVec/WUSTL collaborative work will be to explore how the durability and targeting potential of WUSTL's camelid antibodies can be combined with the strengths of GenVec's gorilla adenovectors to yield precision-targeted compounds that may effectively address a variety of disease indications.

GenVec, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 11:00 AM

GenVec, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 11:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Douglas J. Swirsky, Chief Executive Officer, President, Corporate Secretary and Director.

GenVec, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

GenVec, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, the company reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year. The decrease in revenue for the three-month period ended March 31, 2015 is primarily a result of a decrease in revenue of $1.9 million associated with its hearing loss and balance disorders program with Novartis. This lower revenue resulted mainly from the achievement of a $2 million milestone in the collaboration during the first quarter of 2014, with no corresponding achievement in the first quarter of 2015. This decrease was partially offset by an increase in revenue of $0.2 million associated with its animal health program due to increased work scope. Operating loss was $1.536 million against $0.964 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNVC:US $2.04 USD -0.05

GNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $18.48 USD -0.44
Argos Therapeutics Inc $6.68 USD -0.20
Dynavax Technologies Corp $23.57 USD +0.33
Eurocine Vaccines AB kr2.00 SEK -0.04
Genocea Biosciences Inc $13.52 USD -0.40
View Industry Companies
 

Industry Analysis

GNVC

Industry Average

Valuation GNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENVEC INC, please visit www.genvec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.